AMENDMENTS TO THE CLAIMS

1. (**Currently amended**) A composition for modulating an immune response to a target antigen, comprising a soluble, non-metabolizable carbohydrate or a soluble, non-metabolizable carbohydrate-containing molecule selected from the group consisting of monosaccharides, disaccharides, larger saccharides, synthetic carbohydrates, glycopeptides, N-acetyllactosamine derivatives, modified polysaccharides, starburst dendrimers and glycopolymers, ~~lectin-interactive agent~~ and an immune-modulating agent selected from the group consisting of ~~an antigen that corresponds to at least a portion of~~ the target antigen, a part of the target antigen that elicits an immune response against the target antigen, an antigen-binding molecule that is immuno-interactive with the target antigen and an immune-modulating cell that modulates an immune response to the target antigen, wherein the carbohydrate or carbohydrate-containing molecule ~~lectin-interactive agent~~ and the immune-modulating agent are not conjugated to each other~~with other chemical moieties~~, and wherein the immune-modulating agent produces a greater immune response in the presence of said carbohydrate or carbohydrate-containing molecule than in the absence of said carbohydrate or carbohydrate-containing molecule.

2. (**Currently amended**) A composition according to claim 1, wherein the carbohydrate or carbohydrate-containing molecule binds to a lectin ~~is~~ expressed by an organism.

3. (**Original**) A composition according to claim 2, wherein the organism is selected from the group consisting of bacteria, entamoeba, protozoans, insects, gastropods, plants and animals.

4. (**Original**) A composition according to claim 2, wherein the organism is an animal and the lectin is selected from the group consisting of calnexin, M-type lectins, L-lectins, P-lectins, C-lectins, galactoside-binding lectins, I-type lectins and R-lectins.

5. (**Currently amended**) A composition according to claim 1, wherein the carbohydrate or carbohydrate-containing molecule binds to a lectin ~~is~~ expressed by a cancer or tumor.

6. (**Original**) A composition according to claim 5, wherein the lectin is a galectin.

7. (**Original**) A composition according to claim 6, wherein the galectin is selected from the group consisting of galectin-1, galectin-3 and galectin-9.

8.-10. (**Canceled**)

11. (**Currently amended**) A composition according to claim 1~~8~~, wherein the synthetic carbohydrate is thiodigalactoside.

12.-13. (**Canceled**)

14. (**Currently amended**) A composition according to claim 18, wherein the carbohydrate or carbohydrate- containing molecule is lactulose ~~or synthetic or semi-synthetic analogue thereof~~.

15. (**Currently amended**) A composition according to claim 18, wherein the carbohydrate or carbohydrate- containing molecule is selected from the group consisting of methyl 2-acetamido-2-deoxy-4-*O*-(3-[3-carboxypropanamido]-3-deoxy- β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[{Z}-3-carboxypropenamido]-3-deoxy- β-D-galactopyranosyl)-) β-D- glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-benzamido-3-deoxy-(β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[2-carboxybenzamido]-3-deoxy- β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[4-methoxy-2,3,5,6-tetrafluorobenzamido]-3-deoxy- β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[2-carboxy-3,4,5,6-tetrafluorobenzamido]-3-deoxy- (β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-methane-sulfonamido-3-deoxy-β-D- galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[4-nitrobenzenesulfonamido]-3-deoxy- β-D-galactopyranosyl)- β-D-glucopyranoside, methyl 2- acetamido-2-deoxy-4-*O*-(3-phenylaminocarbonylamino-3-deoxy- β-D-galactopyranosyl)- (β-D-glucopyranoside, methyl 2-acetamido2-deoxy-4-*O*-(2-aminoacetamido-3-deoxy- β-D- galactopyranosyl)- β-D-glucopyranoside, methyl 2-acetamido-2-deoxy-4-*O*-(3-[{2S}-2-amino-3-carboxy-propanamido]-3-deoxy- β-D-galactopyranosyl)- β-D-glucopyranoside and thiodigalactoside.

16. (**Currently amended**) A composition according to claim 1, wherein the carbohydrate or carbohydrate-containing molecule ~~lectin-interactive agent~~ has a binding affinity for the lectin in the range from about 10^{-3} to about 10^{-9} M.

17. (**Currently amended**) A composition according to claim 1, comprising at least two carbohydrate or carbohydrate-containing molecules ~~lectin-interactive agents~~.

18. (**Canceled**)

19. (**Currently amended**) A composition according to claim 17~~18~~, wherein one of the carbohydrate[[s]] or carbohydrate-containing molecules is soluble so that it can diffuse readily through the body of an animal and wherein the other is a larger saccharide that is partially soluble so as to limit its diffusion from the site of delivery to the animal.

20. (**Currently amended**) A composition according to claim 1, wherein the target antigen is selected from the group consisting of a peptide, a polypeptide, a nucleic acid molecule from which any of these is expressible, a whole cell, a pathogen and an antigen-presented by an antigen-presenting cell.

21. (**Original**) A composition according to claim 1, wherein the target antigen is selected from the group consisting of simple intermediary metabolites, sugars, lipids, hormones, macromolecules, phospholipids, nucleic acids, polypeptides and peptides.

22. (**Original**) A composition according to claim 1, wherein the target antigen is selected from the group consisting of endogenous antigens produced by a host and exogenous antigens that are foreign to the host.

23. (**Previously presented**) A composition according to claim 22, wherein the endogenous antigens are selected from the group consisting of self-antigens that are targets of autoimmune responses and cancer or tumor antigens.

24. (**Original**) A composition according to claim 1, wherein the target antigen is expressed by a cancer or a pathogenic organism.

25. (**Original**) A composition according to claim 24, wherein the composition is adapted to stimulate or otherwise enhance an immune response to the target antigen.

26. (**Original**) A composition according to claim 1, wherein the target antigen is associated with an unwanted immune response.

27. (**Original**) A composition according to claim 26, wherein the unwanted immune response is selected from the group consisting of transplant rejection, graft versus host disease, allergies, parasitic diseases, inflammatory diseases and autoimmune diseases.

28. (**Original**) A composition according to claim 27, wherein the composition is adapted to induce a tolerogenic response to the target antigen, wherein the response is selected from the group consisting of an anergic response and the suppression of a future or existing immune response.

29. (**Original**) A composition according to claim 1, wherein the immune-modulating cell is an antigen-presenting cell that stimulates an immune response.

30. (**Original**) A composition according to claim 1, wherein the immune-modulating cell is an antigen-presenting cell that induces a tolerogenic response.

31. (**Original**) A composition according to claim 29, wherein the antigen-presenting cell is a cell to which an immune response is required and which has been optionally modified to enhance its antigen-presenting functions.

32. (**Original**) A composition according to claim 29, wherein the antigen-presenting cell is modified by culturing the cell in the presence of a type II interferon (IFN) and optionally at least one type I IFN for a time and under conditions sufficient to enhance the antigen-presenting function of the cell and washing the cell to remove the IFN.

33. (**Original**) A composition according to claim 29, wherein the antigen-presenting cell is modified by introducing a construct into the cell from which one or more IFNs selected from a type II IFN and a type I IFN are expressible.

34. (**Original**) A composition according to claim 29, wherein the antigen-presenting cell is an allogeneic antigen-presenting cell or cell line that shares major and/or minor histocompatability antigens to a recipient of the composition.

35. (**Original**) A composition according to claim 1, wherein the immune-modulating cell is an immune effector cell selected from the group consisting of T lymphocytes and B lymphocytes.

36. (**Original**) A composition according to claim 35, wherein the T lymphocytes are selected from the group consisting of cytolytic T lymphocytes helper T lymphocytes and T regulatory cells.

37. (**Original**) A composition according to claim 1, wherein the antigen-binding molecule binds to or otherwise interacts with the target antigen so as to reduce its level or functional activity.

38. (**Original**) A composition according to claim 1, further comprising one or more immunoregulatory molecules selected from the group consisting of co-stimulatory molecules, cytokines and co-inhibitory molecules.

39. (**Original**) A composition according to claim 38, wherein the co-stimulatory molecules are selected from the group consisting of B7-1, B7-2, B7-3, ICAM-1 and ICAM-2.

40. (**Previously presented**) A composition according to claim 38, wherein the cytokines are selected from the group consisting of interferons, granulocyte/macrophage-colony stimulating factor (GM-CSF), interleukin-10 and tumor necrosis factor α (TNF-α).

41. (**Original**) A composition according to claim 38, wherein the co-inhibitory molecules are selected from the group consisting of OX-2 and programmed death-1 ligand (PD-1L).

42. (**Original**) A composition according to claim 38, wherein the immunoregulatory molecule (s) is/are provided in soluble form.

43. (**Original**) A composition according to claim 38, wherein the immunoregulatory molecule (s) is/are produced intracellularly from an expression construct or vector.

44. (**Original**) A composition according to claim 1, further comprising an adjuvant.

45. (**Original**) A composition according to claim 1, further comprising a pharmaceutically acceptable carrier.

46. (**Withdrawn**) A method for modulating an immune response to a target antigen in a subject, comprising administering to the subject a composition according to Claim 1.

47. (**Withdrawn- Currently amended**) A method according to claim 46, wherein the carbohydrate or carbohydrate-containing molecule ~~lectin-interactive agent~~ and the immune-modulating agent are ~~is~~ administered sequentially, separately or simultaneously.

48. (**Withdrawn**) A method according to claim 46, which is used for the treatment or prophylaxis of a disease or condition associated with the presence or aberrant expression of the target antigen in a subject.

49. (**Withdrawn**) A method according to claim 48, wherein the disease or condition is treated or prevented by using a composition that stimulates or otherwise enhances an immune response to the target antigen.

50. (**Withdrawn**) A method according to claim 48, wherein the disease or condition is selected from the group consisting of a pathogenic infection, a disease characterized by immunodeficiency and a cancer or tumor.

51. (**Withdrawn**) A method according to claim 48, wherein the disease or condition is treated or prevented by using a composition that elicits a tolerogenic response to the target antigen.

52. (**Withdrawn**) A method according to claim 48, wherein the disease or condition is selected from the group consisting of transplant rejection, graft versus host disease, allergies, parasitic diseases, inflammatory diseases and autoimmune diseases.

53.-64. (**Canceled**)